Quotes 5-day view Delayed Nasdaq
02/23/2021
02/24/2021
02/25/2021
02/26/2021
03/01/2021
Date
11.48(c)
11.76(c)
11.65(c)
11.84(c)
11.95(c)
Last
117 438
99 825
84 730
142 625
176 711
Volume
-3.04%
+2.44%
-0.94%
+1.63%
+0.93%
Change
Sales 2020
18,7 M
-
-
Net income 2020
-48,3 M
-
-
Net Debt 2020
-
-
-
P/E ratio 2020
-6,34x
Yield 2020
-
Sales 2021
16,2 M
-
-
Net income 2021
-66,8 M
-
-
Net Debt 2021
-
-
-
P/E ratio 2021
-4,94x
Yield 2021
-
Capitalization
399 M
399 M
-
Capi. / Sales 2020
21,4x
Capi. / Sales 2021
24,6x
Nbr of Employees
95
Free-Float
72,4%
HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is developing products to prevent and cure infectious diseases and cancer. The Company's infectious and oncology product candidates HB-101, HB-201 and HB-202. The infectious disease product candidate, HB-101, is in a randomized, double-blinded Phase II clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation...
Notations Surperformance© of HOOKIPA Pharma Inc.
Trading Rating :
Investor Rating :
All news about HOOKIPA PHARMA INC.
News in other languages on HOOKIPA PHARMA INC.
- No features available -
Analyst Recommendations on HOOKIPA PHARMA INC.
Chart HOOKIPA PHARMA INC.
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends HOOKIPA PHARMA INC.
Short Term Mid-Term Long Term Trends Neutral Neutral Bullish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
BUY
Number of Analysts
6
Average target price
22,00 $
Last Close Price
11,95 $
Spread / Highest target
134%
Spread / Average Target
84,1%
Spread / Lowest Target
33,9%
Please enable JavaScript in your browser's settings to use dynamic charts.